ARMP — Armata Pharmaceuticals, Inc.
—
NYSE ·
Health Care ·
Biotechnology ·
CIK 921114 ·
Last close
$2.66
Market Cap
$98.93M
52W High
$14.98
52W Low
$2.40
ADV30
95,596
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -7,383,000 | 54,857,000 | 84,478,000 | 18,317,000 | 258,606,000 |
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 0 | — | -8,785,000 | -115,346,000 | 69,800,000 | 4,754,000 | 381,386,000 |
| Dec 2025 | 0 | — | -8,411,000 | -124,298,000 | 76,882,000 | 8,688,000 | 295,478,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-23,965,000
Investing CF
$-506,000
Financing CF
$16,267,000
CapEx
$-506,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.62
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-616,880,000
Inventory
—
Receivables
$47,000
ST Investments
—
EBIT TTM
$-264,067,000
Pretax Income TTM
$-282,614,000
Interest Exp TTM
$18,547,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,555,000
EBITDA
$-32,853,000
Free Cash Flow
$-30,552,376
Enterprise Value
$377,201,472
Total Cash
$18,317,000
Total Debt
$251,583,008
Shares Out
37,192,632
Trailing EPS
$-4.17
Book Value
$-4.68
ROE
—
ROA
-25.1%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -31,222,000 | -173,799,000 | 76,882,000 | 295,478,000 | -218,596,000 | -25,763,000 |
| Dec 2024 | 0 | -42,436,000 | -18,916,000 | 86,437,000 | 134,456,000 | -48,019,000 | -37,551,000 |
| Dec 2023 | 0 | -40,890,000 | -69,045,000 | 98,363,000 | 130,428,000 | -32,065,000 | -47,423,000 |
| Dec 2022 | 0 | -36,946,000 | -36,917,000 | 95,834,000 | 59,754,000 | 36,080,000 | -32,481,000 |
TTM Snapshot
Revenues TTM
$5,543,000
NetIncome TTM
$-192,178,000
OpCashFlow TTM
—
Assets (Latest)
$89,950,000
Forward EPS
$-2.04
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZURA | Zura Bio Ltd | $99.70M | $1.03 | — |
| VYGR | Voyager Therapeutics, Inc. | $94.59M | $1.52 | — |
| CMPX | Compass Therapeutics, Inc. | $109.26M | $0.61 | — |
| MOLN | MOLECULAR PARTNERS AG | $109.55M | $2.86 | — |
| LENZ | LENZ Therapeutics, Inc. | $109.97M | $3.50 | — |
News headlines (Yahoo Finance, 1h cache)
Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update
2026-11-12 21:05 · Yahoo
Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States
2026-10-07 11:00 · Yahoo
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
2026-09-23 11:00 · Yahoo
Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
2026-09-21 11:00 · Yahoo
Armata Pharmaceuticals Shares Rise 8% After FDA Grants AP-SA02 Breakthrough Therapy Designation
2026-09-14 13:34 · Yahoo
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
2026-09-14 11:00 · Yahoo
Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-10 11:00 · Yahoo
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
2026-09-03 11:00 · Yahoo
Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?
2026-07-21 11:05 · Yahoo
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
2026-07-20 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.